Últimas noticias sobre UiPath (NYSE:PATH) Bolsa

UIPATH INC - CLASS A

UiPath

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

Ark Invest's Cathie Wood Says Belief In Bitcoin's $1.5 Million Price Target By 2030 Has Grown

Equities

News

Markets

ETFs

ARKG

ARKK

GTLB

ILMN

IRDM

PATH

Ark Invest realizó movimientos estratégicos en el sector tecnológico, ajustando su portafolio con compras clave y ventas millonarias.

Cathie Wood apuesta por Tempus AI y AMD mientras reduce su posición en Meta

Stock Movers

Pre-Market Outlook

Movers

Trading Ideas

ADTX

ANAB

ANIK

ANNA

AREB

ASBP

CDLX

ELME

FAMI

HEPA

INTC

NOVA

SGBX

SNES

STGW

YOSH

Intel designa un nuevo CEO y sus acciones suben con fuerza en el premercado. Descubre qué otros valores destacan hoy.

Las acciones de Intel suben más del 10%; 20 acciones que se están moviendo en el premercado

PLTR

ROKU

TWST

Ark Invest vendió más de 135.000 acciones de Palantir Technologies Inc. tras su récord en bolsa. ¿Estrategia o señal de alerta?

Cathie Wood reduce posición en Palantir (PLTR) tras resultados récord: ¿Oportunidad o advertencia?

UiPath Inc

Pathfinder Bancorp Inc

PATHFINDER CELL THERAPY by Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy Inc

Pathfinder Ventures Inc

PATHFINDER VENTURES INC by PATHFINDER VENTURES INC.

Pathward Financial Inc

UiPath's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) short percent of float has fallen 10.98% since its last report. The company recently reported that it has 30.36 million shares sold short, which is 7.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>UiPath Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743014724_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UiPath has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing UiPath's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, UiPath's peer group average for short interest as a percentage of float is 5.45%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on UiPath?

RBC Capital analyst Matthew Hedberg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and maintains $13 price target.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Sector Perform on UiPath, Maintains $13 Price Target

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

Needham Reiterates Hold on UiPathto Hold

<a href="https://www.uipath.com/newsroom/coronis-health-enhances-healthcare-delivery-systems-through-uipath-platform" title="https://www.uipath.com/newsroom/coronis-health-enhances-healthcare-delivery-systems-through-uipath-platform">https://www.uipath.com/newsroom/coronis-health-enhances-healthcare-delivery-systems-through-uipath-platform</a>

'Coronis Health Enhances Healthcare Delivery Systems Through UiPath Platform' - UiPath

On Friday, Mar. 14, 2025, the&nbsp;Cathie Wood-led&nbsp;Ark Invest&nbsp;made significant trades involving&nbsp;GitLab Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>),&nbsp;Intellia Therapeutics Inc&nbsp;(NGM: NTLA),&nbsp;Prime Medicine Inc&nbsp;(NGM: PRME),&nbsp;UiPath Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>),&nbsp;Ibotta Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBTA#NYSE">IBTA</a>),&nbsp;Roblox Corp&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>),&nbsp;Repare Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), and&nbsp;CareDx Inc&nbsp;(NGM: CDNA).
The PATH Trade:&nbsp;Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) funds sold shares of UiPath Inc. The ARKK fund sold 1,092,269 shares, while the ARKW fund sold 158,650 shares.
With the stock closing at $10.88, the total value of the sold shares was approximately $13.61 million.
The RBLX Trade:&nbsp;Ark Invest&#8217;s ARK Fintech Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKF#NYSE">ARKF</a>) and ARKW funds sold shares of Roblox Corp. The ARKF fund sold 10,057 shares, while the ARKW fund sold 28,700 shares.
With the stock closing at $56.51, the total value of the sold shares was approximately $2.19 million.
The GTLB Trade:&nbsp;Ark Invest&#8217;s ARKK fund bought 81,543 shares of GitLab Inc, with the stock closing at $52.08. This translated to an investment of approximately $4.24 million.
The ARKW fund also purchased 22,610 shares of GitLab Inc, amounting to an investment of around $1.18 million.
The NTLA Trade:&nbsp;The ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) and ARKK funds of Ark Invest bought shares of Intellia Therapeutics Inc. The ARKG fund acquired 11,276 shares, while the ARKK fund purchased 56,244 shares.
With the stock closing at $9.14, the total investment was approximately $0.62 million.
The PRME Trade:&nbsp;Ark Invest&#8217;s ARKK fund sold 46,026 shares of Prime Medicine Inc. The stock closed at $1.79, making the total value of the sold shares around $82,386.
The IBTA Trade:&nbsp;Ark Invest&#8217;s ARKF and ARKW funds bought shares of Ibotta Inc. The ARKF fund acquired 10,967 shares, while the ARKW fund purchased 68,234 shares.
With the stock closing at $37.87, the total investment was approximately $2.99 million.
The RPTX Trade:&nbsp;Ark Invest&#8217;s ARKG fund sold 53,449 shares of Repare Therapeutics Inc.
The stock closed at $1.1, making the total value of the sold shares around $58,794.
The CDNA Trade:&nbsp;Ark Invest&#8217;s ARKG fund sold 47,153 shares of CareDx Inc. The stock closed at $18.9, making the total value of the sold shares around $891,191.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44345022/ray-dalio-has-a-chilling-warning-for-president-trump-debt-crisis-is-imminent-and-an-issue-of-paramount-importance">Ray Dalio Has A Chilling Warning For President Trump: Debt Crisis Is Imminent, And An Issue Of &#8216;Paramount Importance&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

ARKF

ARKW

CDNA

IBTA

NTLA

PRME

RBLX

RPTX

Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta

WIIM

AMBA

AMPG

ANET

APLD

ARQQ

ASNS

AVPT

AXTI

BNZI

BRZE

BTOG

CDNS

CRDO

CSAI

DDOG

ERIC

FCUV

GRRR

INFA

IONQ

LITE

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

MCHP

MNDY

MOBBW

MSFT

MVIS

NVTS

OSIS

PCOR

PONY

QUBT

RCAT

RGTI

SITM

SMCI

SNOW

SPSC

TRMB

VERI

VNET

WDAY

WOLF

WRAP

WULF

YAAS

Shares of companies in the broader technology sector are trading higher. The sector may be rising as the overall market rebounds after falling recently on tariff concerns.

BMO Capital analyst Keith Bachman maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Market Perform and lowers the price target from $16 to $11.5.

BMO Capital Maintains Market Perform on UiPath, Lowers Price Target to $11.5

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the &#8220;Extreme Fear&#8221; zone on Thursday.
U.S. stocks settled lower on Thursday, with the Dow Jones index falling more than 500 points during the session following the release of economic data.
U.S. producer prices came in unchanged in February from January compared to a revised 0.6% increase in the previous period and versus estimates of a 0.3% gain. U.S. initial jobless claims declined by 2,000 to 220,000 in the first week of March, compared to market estimates of 225,000.
On Thursday, U.S. President Donald Trump threatened to impose a 200% tariff on European wine and spirits imports unless the EU eliminates its 50% tariff on U.S. whiskey.
Shares of Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) gained around 7% on Thursday after the company reported better-than-expected fourth-quarter sales results. UiPath Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares dipped around 16% after the company reported a fourth-quarter revenue miss and issued first-quarter revenue guidance below estimates.
Most sectors on the S&amp;P 500 closed on a negative note, with consumer discretionary, real estate and communication services stocks recording biggest losses on Thursday. However, utilities stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 537 points to 40,813.57 on Thursday. The S&amp;P 500 fell 1.39% to 5,521.52, while the Nasdaq Composite dipped 1.96% at 17,303.01 during Thursday's session.
Investors are awaiting earnings results from Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), RLX Technology Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) and The Buckle, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKE#NYSE">BKE</a>) today.
At a current reading of 14.8, the index remained in the &#8220;Extreme Fear&#8221; zone on Thursday, versus a prior reading of 20.7.
What is CNN Business Fear &amp; Greed Index?
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

Earnings

Dow Tumbles Over 500 Points On Tariff Threats; Fear Continues To Grip Markets, Fear & Greed Index Remains In 'Extreme Fear' Zone

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are trading lower Thursday after the company reported fourth-quarter revenue and issued lower-than-expected revenue guidance <a href="https://www.benzinga.com/25/03/44311508/uipath-hit-by-slowing-arr-growth-and-deal-timing-woes-but-ai-and-cloud-spark-optimism">for the first quarter. </a>
What To Know: Despite beating earnings estimates with quarterly earnings of nine cents per share versus the expected three cents, UiPath&#8217;s revenue came in at $424 million, just short of the analyst consensus of $425.36 million. This increased from $405.25 million in the same quarter last year.
CEO Daniel Dines highlighted that fiscal 2025 was one of the company&#8217;s most innovative years, citing the launch of new AI-driven automation products, including Autopilot, Agent Builder, Agentic Orchestration and Agentic Testing. UiPath also announced the acquisition of Peak, an AI-native company, although no specific financial terms were disclosed.
Despite these developments, investors reacted negatively to the company's first-quarter revenue guidance, which is projected between $330 million and $335 million, significantly below the $368.08 million consensus estimate. 
PATH Price Action: Uipath shares were down 14.0% at $10.18 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-1024x534.png" alt="" class="wp-image-823745" style="width:456px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/13143838/Screenshot-2025-03-13-at-14.38.07.png 1514w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44311699/wall-streets-downward-slide-returns-gold-breaks-records-intel-skyrockets-on-ceo-appointment-whats-driving-markets-thursday">Wall Street&#8217;s Downward Slide Returns, Gold Breaks Records, Intel Skyrockets On CEO Appointment: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image Via Shutterstock.

UiPath Shares Drop After Q4 Revenue Miss And Weak Q1 Guidance: What's Going On?

UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) stock price declined Thursday after the company reported a <a href="https://www.benzinga.com/news/earnings/25/03/44290549/uipath-shares-plunge-after-q4-revenues-miss-weak-q1-guidance" target="_blank" rel="noreferrer noopener">fourth-quarter revenue</a> miss.
The New York-based company issued first-quarter revenue guidance below estimates on Wednesday.It reported largely disappointing fourth-quarter results, predominantly driven by deal delays in its US Fed segment.
These delays also drove initial fiscal 2026 guidance below estimates due to additional uncertainty of deal timing for this vertical.
Also Read: <a href="https://www.benzinga.com/25/03/44209166/cathie-wood-led-ark-invest-roblox-roku-uipath-as-markets-take-a-dip" target="_blank" rel="noreferrer noopener">Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip</a>
Needham analyst Scott Berg reiterated UiPath <a href="https://www.benzinga.com/quote/PATH/analyst-ratings" target="_blank" rel="noreferrer noopener">with a Hold</a>.
Total revenues of $423.6 million were below his $425.3 million estimate. Berg noted currency exchange rate fluctuations had a negative $2 million impact on revenues. When adjusting a similar effect to ARR, the net new ARR of $59 million was ~$5 million below guidance.
On the optimistic side, customers are now using 3k of UiPath&#8217;s Agents, which the analyst noted as a strong initial interest in Agentic innovations. The analyst would expect the small pilots to expand substantially in the second half of 2026.
UiPath also noted stronger-than-expected growth of its Cloud model, with ARR up more than 50%, which Berg said was a catalyst to incremental AI adoption since much of the innovation is better served in the Cloud. The fourth-quarter revenue and adjusted EPS were $423.6 million and $0.26, compared to the analyst&#8217;s $425.3 million and $0.19 estimates.
Total revenue increased by 4.5%, subscription revenue grew by 22.3%, and license revenue went down by 10.2%.
ARR grew 13.8% to $1.67 billion, a deceleration from the 16.6% growth in the third quarter and the 21.6% growth seen last year. Net new ARR of $59 million represents a 31% decline.
The customer count of 10,750 decreased by 140 sequentially and was down 0.7% compared to last year.
To date, customers have deployed over 3,000 agents on the UiPath platform. Overall, AI has a 20% customer attach rate, with a greater than 85% attach rate for customers with over $1 million in ARR.
UiPath&#8217;s acquisition of AI-native company Peak has a relatively small impact on fiscal 2026 financials, given that it falls under the regulatory threshold on financial disclosure.
UiPath is facing elevated levels of uncertainty driven by public sector dynamics, macro volatility, and currency exchange rate fluctuations. Revenue growth guidance of 6.8% to $1.525 billion—$1.530 billion missed the consensus $1.584 billion forecast.
Price Action: PATH stock is down 14.54% at $10.11 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/25/03/44305045/archer-taps-palantirs-ai-to-supercharge-electric-aircraft-production-and-flight-tech" target="_blank" rel="noreferrer noopener">Archer Taps Palantir&#8217;s AI to Supercharge Electric Aircraft Production and Flight Tech</a></li>
</ul>
Image: Courtesy of UiPath, Inc.

Tech

UiPath Hit By Slowing ARR Growth, Deal Timing Woes: Analyst Remains Optimistic For AI, Cloud Spark

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are <a href="https://www.benzinga.com/quote/PATH/analyst-ratings" target="_blank" rel="noreferrer noopener">trading lower on Thursday.</a>
The company released its fourth-quarter results<a target="_blank" href="https://www.benzinga.com/news/earnings/25/03/44290549/uipath-shares-plunge-after-q4-revenues-miss-weak-q1-guidance" rel="noreferrer noopener"> after Wednesday&#8217;s closing bell.</a> Here&#8217;s a look at the key figures&nbsp;from the report.&nbsp;&nbsp;
UiPath reported quarterly earnings of&nbsp;nine&nbsp;cents per share, which beat the analyst consensus estimate of&nbsp;three&nbsp;cents.
Quarterly revenue of $424 million missed the analyst consensus estimate of&nbsp;$425.36 million&nbsp;and is an&nbsp;increase over revenue of&nbsp;$405.25 million from&nbsp;the same period last year.
Scotia Bank analyst Nick Altmann reiterated the Sector Perform rating on the stock, lowering the price forecast to $12 from $15.
Altmann expresses caution about rewarding UiPath for its margin improvements, given that medium-term concerns persist regarding the company&#8217;s ability to effectively transition into AI, with growth continuing to face pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/technicals/25/03/44308689/stock-of-the-day-is-dollar-tree-set-to-move-higher" rel="noreferrer noopener">Stock Of The Day: Is Dollar Tree Set To Move Higher? (Updated)</a>
While the analyst acknowledges the company&#8217;s 9% ARR growth forecast, which aligns with its guidance, and a second-half weighted NNARR guide, Altmann highlights the stock is likely to remain range-bound.
The analyst notes the public sector represents UiPath&#8217;s third-largest vertical, although management refrains from specifying the exact mix. Given the ongoing macroeconomic pressures, management is adopting a more cautious approach to its guidance.
Additionally, the analyst highlights a dip in NRR, which fell to 110% from the previous 113%.
The low-end segment continues to face challenges, as evidenced by a decline in net adds, with a drop of 40 this quarter compared to a smaller loss of 20 in the prior quarter.
Despite these concerns, the analyst acknowledges margins remain a positive aspect, with record operating margins of 32%, and the FY26 guidance of approximately 18%, which is above the consensus of 15%. 
The primary focus for the company continues to be stabilizing growth, which has yet to materialize, Altmann adds.
PATH Price Action: UiPath shares are trading lower by 14.38% to $10.15 at publication Thursday.
Read Next:
• <a href="https://www.benzinga.com/government/regulations/25/03/44301835/trump-threatens-200-tariff-on-european-wine-alcohol-stocks-react" target="_blank" rel="noreferrer noopener">Trump Threatens 200% Tariff On European Wine, Alcohol Stocks React</a>

Photo: Courtesy of UiPath, Inc.

Analyst Color

General

UiPath Stock Down: Faces Caution Despite Margin Gains, Analyst Doubtful About Company's AI Transition Capability

RBC Capital analyst Matthew Hedberg maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and lowers the price target from $16 to $13.

RBC Capital Maintains Sector Perform on UiPath, Lowers Price Target to $13

<h3>Gainers</h3>
<ul>
<li>Quantum (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares increased by 36.0% to $15.32 during Thursday's regular session. The market value of their outstanding shares is at $89.3 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) shares moved upwards by 16.38% to $0.93. The company's market cap stands at $60.0 million. </li>
<li>U-BX Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBXG#NASDAQ">UBXG</a>) shares moved upwards by 16.03% to $3.62. The company's market cap stands at $12.2 million. </li>
<li>Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) shares rose 14.96% to $23.77. The company's market cap stands at $102.9 billion. </li>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) stock moved upwards by 14.42% to $1.12. The company's market cap stands at $19.6 million. </li>
<li>Wellchange Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) stock increased by 13.28% to $0.52. The market value of their outstanding shares is at $24.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock declined by 22.8% to $0.28 during Thursday's regular session. The market value of their outstanding shares is at $2.4 million. </li>
<li>A10 Networks (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATEN#NYSE">ATEN</a>) stock decreased by 16.98% to $16.23. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares declined by 15.27% to $0.29. The company's market cap stands at $7.3 million. </li>
<li>UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) stock declined by 14.2% to $10.15. The company's market cap stands at $5.5 billion. As per the news, the Q4 earnings report came out yesterday. </li>
<li>ZenaTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) shares decreased by 13.35% to $3.96. The company's market cap stands at $69.9 million. </li>
<li>AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) shares fell 13.2% to $11.03. The company's market cap stands at $134.3 million. As per the press release, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEYE

ATEN

INTZ

QMCO

TDTH

UBXG

ZENA

12 Information Technology Stocks Moving In Thursday's Intraday Session

U.S. stocks traded lower midway through trading, with the S&amp;P 500 falling more than 1% on Thursday.
The Dow traded down 1.17% to 40,865.63 while the NASDAQ dipped 1.64% to 17,359.52. The S&amp;P 500 also fell, dropping, 1.18% to 5,533.34.
Check This Out: <a href="https://www.benzinga.com/25/03/44298504/top-3-health-care-stocks-youll-regret-missing-this-quarter">Top 3 Health Care Stocks You&#8217;ll Regret Missing This Quarter</a>
Leading and Lagging Sectors Materials shares gained by 0.9% on Thursday.
In trading on Thursday, consumer discretionary shares dipped by 1.4%.
Top Headline
Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) reported better-than-expected fourth-quarter sales results.
The company reported fourth-quarter sales growth of 4.5% year-on-year to $10.304 billion, beating the analyst consensus estimate of $10.264 billion. EPS of $0.87 missed the consensus estimate of $1.51.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Lifeward Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFWD#NASDAQ">LFWD</a>) shares shot up 78% to $2.63 as the company received 510(k) FDA clearance for the newest generation of its Personal Exoskeleton Device, The ReWalk 7.</li>
<li>Shares of Aveanna Healthcare Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAH#NASDAQ">AVAH</a>)got a boost, surging 24% to $4.63 after the company reported better-than-expected fourth-quarter sales results.</li>
<li>MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) shares were also up, gaining 23% to $7.87 after the company reported FY24 financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares dropped 36% to $0.0363 after the company announced a 1-for-250 reverse stock split.</li>
<li>Shares of Century Casinos, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) were down 28% to $1.7588 after the company reported weak fourth-quarter financial results.</li>
<li>UiPath Inc. &nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) was down, falling 16% to $10.00 after the company reported a fourth-quarter revenue miss and issued first-quarter revenue guidance below estimates.</li>
</ul>
Commodities In commodity news, oil traded down 1% to $67.03 while gold traded up 0.4% at $2,959.80.
Silver traded down 0.2% to $33.680 on Thursday, while copper rose 0.1% to $4.8555.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.11%, Germany's DAX 40 fell 0.93% and France's CAC 40 fell 0.65%. Spain's IBEX 35 Index rose 0.29%, while London's FTSE 100 rose 0.11%.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei dipping 0.08%, China's Shanghai Composite Index falling 0.39% and Hong Kong's Hang Seng Index falling 0.58%, India's BSE Sensex falling 0.27%.
Economics
<ul>
<li>U.S. producer prices came in unchanged in February from January compared to a revised 0.6% increase in the previous period and versus estimates of a 0.3% gain.</li>
<li>U.S. initial jobless claims declined by 2,000 to 220,000 in the first week of March, compared to market estimates of 225,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday">Adobe, Intel And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Eurozone

Commodities

Intraday Update

AVAH

CNTY

LFWD

MGTX

Crude Oil Falls 1%; Dollar General Posts Upbeat Sales

Canaccord Genuity analyst Kingsley Crane maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Buy and lowers the price target from $19 to $14.

Canaccord Genuity Maintains Buy on UiPath, Lowers Price Target to $14

Evercore ISI Group analyst Kirk Materne maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a In-Line and lowers the price target from $16 to $12.

Evercore ISI Group Maintains In-Line on UiPath, Lowers Price Target to $12

Scotiabank analyst Nick Altmann maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and lowers the price target from $15 to $12.

Scotiabank Maintains Sector Perform on UiPath, Lowers Price Target to $12

UBS analyst Jeff Hickey maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sell and lowers the price target from $14 to $10.

UBS Maintains Sell on UiPath, Lowers Price Target to $10

Wells Fargo analyst Michael Turrin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and lowers the price target from $13 to $11.

Wells Fargo Maintains Equal-Weight on UiPath, Lowers Price Target to $11

Barclays analyst Raimo Lenschow maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and lowers the price target from $15 to $12.

Barclays Maintains Equal-Weight on UiPath, Lowers Price Target to $12

Press Releases

President Trump Unveils $500 Billion AI Infrastructure: Watch AI, PRSO, BBAI Among The Giants

UiPath Report Reveals Agentic AI is Driving Investment to Tackle More Complex Business Workflows

UiPath to Showcase How Agentic Automation is Transforming the Healthcare Industry at ViVE 2025 Conference

UiPath Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results Conference Call

UiPath Expands Healthcare Automation with New Global Professional Services Capabilities for Electronic Medical Records Platform

UiPath Acquires Peak to Launch Vertically Specialized Agents within its Agentic Automation Platform

UiPath Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

How Agents are Accelerating Enterprise-Wide Transformation: UiPath to Unveil Latest Agentic Automation Solutions at Agentic AI Summit

UiPath Offers Complimentary Trial of Automation Cloud Public Sector to Assist U.S. Government Agencies' Efficiency Initiatives

Comments

UiPath

Noticias

Últimas noticias sobre UiPath (NYSE:PATH) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL